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ABSTRACT
Background: To review the literature reporting SWAP and FDT for the early detection of
visual field loss in glaucoma.
Methods: A review of literature published on Medline, Scopus and Web of Science
between 1966 and present was undertaken with only articles in the English language
reviewed.
Results: SWAP has high inter and intra subject variability. There is no uniform decision
as to what criteria should be applied to define abnormal visual fields. In comparison with
standard automated perimetry (SAP) there is controversy as to whether SWAP is reliable
in detecting glaucomatous damage. As a screening tool FDT may have potential due to its
short testing time and lower test-retest variability. There is a lack of definitive abnormality
criteria to define visual field loss with FDT. First and second generation FDT have been
found to be comparable to SWAP in terms of diagnostic sensitivity. There is a lack of
studies comparing FDT to SAP with longitudinal follow up of visual fields which make it
difficult to determine its reliability in identifying pre-perimetric glaucomatous damage.
Conclusion: There is a need for further longitudinal studies on both SWAP and FDT to
determine fully their reliability in detecting early visual field loss in glaucoma before SAP.
Review Article
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1. INTRODUCTION
Primary open angle glaucoma (POAG) is a chronic, potentially blinding condition caused by
death of ganglion cells and their axons within the optic nerve due to increased pressure
within the eye [1]. It affects approximately 3% of people over 65 in the UK and with average
life expectancy in the UK rising, more people are now living with glaucoma even compared
tothe mid-90’s [2,3]. The cost of treating glaucoma in the UK is more than £300 million per
year. This includes both direct (medication, outpatient care, routine assessment and surgical
procedures) and indirect treatment (cost of low vision services, loss of earnings resulting
from vision loss) [4,5]. Glaucoma also affects quality of life with partial sight or registered
severely sight impaired being ultimate possibilities. One of the determinants for a poor visual
prognosis is signs of glaucomatous field damage upon presentation to the clinician. This
means vision and visual field could be potentially saved if damage could be reliably detected
before current visual field analysis is able to [6,7]. Glaucoma diagnosis and progression are
determined by three factors; intraocular pressure (IOP) changes, optic disc examination and
visual field evaluation. There are a number of methods which can be used to evaluate the
visual field including standard automated threshold perimetry, frequency doubling
technology, critical flicker frequency, short wavelength automated perimetry, high pass
resolution perimetry and motion automated perimetry amongst others.
Within the visual pathway there are a number of sub-pathways that subserve different
aspects of vision and whose physiological properties are distinct. The M (magnocellular)
pathway consists of larger retinal ganglion cells that are mainly linked with visual perception
and respond predominantly to motion and coarse outlines. They are regarded as insensitive
to colour stimuli in balanced luminance conditions, respond to high contrast sensitivity and
resolve higher temporal and lower spatial frequencies[8,9]. The K (koniocellular) pathway
consists of smaller, sparse retinal ganglion cells that are sensitive to short wavelengths
(S/blue cones) [8-10]. The spatial and temporal resolutions of the K pathway overlap with the
M and P pathways [11]. The P (parvocellular) pathway consists of small retinal ganglion cells
that are sensitive to colour (particularly red/green), respond predominantly to fine details and
to lower contrast sensitivity. They resolve lower temporal and higher spatial frequencies
[8,9]. It is possible to isolate responses from the M, P and K pathways by using different
testing stimuli. Strategies to isolate the P and K pathways include the use of coloured, high
contrast, small stimuli whereas strategies to isolate the M pathway include the use of stimuli
that are colour neutral, have high temporal and low spatial frequencies such as large, fast
motion reversal, low contrast targets.
It is known that in early glaucoma, larger ganglion cells within the optic nerve are damaged.
First the blue-yellow ganglion cells (part of the koniocellular pathway) which are larger than
red-green ganglion cells are damaged leading to dyschromatopsia [12]. This effect has been
exploited in testing for early glaucoma damage by using short wavelength automated
perimetry (SWAP). SWAP is used with blue points (wavelength 440nm) with a narrow band
presented for 200msec on a yellow background (100cd/m2) to try and detect early colour
vision loss [3]. Studies have shown that SWAP perimetry can detect glaucomatous damage
3-5 years before conventional white on white perimetry [13-15]. With current standard white
on white perimetry around 30-50% of ganglion cells have been destroyed before detection
[16].
McBride and Rowe; OR, Article no. OR.2014.003
80
Furthermore, the M pathway can be isolated when assessing for early glaucoma. Frequency
doubling technology (FDT) was first described by Kelly over 45 years ago. It is based on the
fact that when an achromatic sinusoidal grating of low spatial frequency undergoes flickering
at high temporal frequency the apparent spatial frequency of the grating appears to double
[17]. The response to this is thought to be mediated by My-cells, which are sensitive to lowcontrast and motion stimulus. My cells are again larger than other retinal ganglion cells (partof the magnocellular pathway) and are therefore more prone to damage in early glaucoma
[18]. This forms the rationale for using FDT as a potential visual field screening method for
early glaucoma detection.
There is an alternative theory as to why SWAP and FDT may be able to detect early
glaucomatous damage: as a result of the reduction in the redundancy in the visual system
[19]. The function-specific tests isolate a subset of ganglion cells which may lead to an
increased sensitivity to early ganglion cell loss.
There has been conflicting evidence regarding the use of SWAP and FDT for early detection
of visual field loss. The aim of this review is to evaluate the literature in respect to whether
FDT and SWAP perimetry can reliably detect glaucomatous visual field changes before
Humphrey SAP.
2. METHODOLOGY
The SCOPUS, Web of Science, PubMed and Medline databases were searched for the
following terms: SWAP and glaucoma, Short Wavelength Automated Perimetry and
glaucoma, SWAP and ocular hypertension and Short Wavelength Automated Perimetry and
ocular hypertension, SWAP and open angle glaucoma, SWAP and closed angle glaucoma,
Frequency Doubling Technology and glaucoma, FDT and ocular hypertension, Frequency
Doubling Technology and open angle glaucoma, Frequency Doubling Technology and angle
closure glaucoma, Frequency Doubling Technology and Short Wavelength Automated
Perimetry, Frequency Doubling Technology and screening, Matrix FDT and ocular
hypertension, Matrix FDT and glaucoma and Matrix FDT and closed angle glaucoma.
We included international articles but only those written in English were reviewed due to lack
of access to translation facilities. The years included were from the year 1966 to 2013. In this
review only studies reporting the use of SWAP and/or FDT for early visual field loss in
glaucoma detection are considered.
We found 2917 articles from our search, accessed 112 full articles which were assessed as
relevant to the review topic and evaluated 79 articles for this review article.
3. RESULTS AND DISCUSSION
3.1 Short Wavelength Automated Perimetry (SWAP)
SWAP is a type of visual field assessment which is based on the principle that larger
ganglion cells within the retina are selectively damaged during early glaucoma. Ten per cent
of these larger ganglion cells belong to the blue-yellow pathway: part of the koniocellular
pathway [12]. The earlier death of this ganglion cell population has also been confirmed by
histological evidence [20-22]. The blue-yellow conditions of SWAP isolate the S cone system
(short wavelength cones), reduce the participation of other cone systems (red – long
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wavelength and green – medium wavelength) and saturate the rods activity through the
adaptation to yellow light [23,24].This phenomenon has been reported to be of use to predict
glaucomatous visual field damage up to 4 years before it is detected on standard achromatic
perimetry [13,14].
SWAP can be performed on the Humphrey Visual Field Analyser (HVF: Carl Zeiss Meditec
Inc., Dublin, CA, USA) and the Octopus perimeter (Haag Streit Int., USA). A Goldman size V
target (1.74º diameter) is used with a blue filter placed over the source of light allowing only
light with a peak transmission of 440nm through. The white background light is replaced by
yellow light illuminated at 100 cdm2 in the perimeter bowl. The targets are presented for
200msec in all test locations. The test is performed within the central 30 degrees of the
visual field.
SWAP has not been introduced routinely into clinical practice due to a number of factors:
clinicians are not united on a definition of abnormality criteria [25], the effect of the ageing
lens on results [26], lengthy test time [24], patient fatigue and patient’s dislike of the test [27]
and the large intra and inter-subject variability even with normal subjects [28] which make it
difficult to define an abnormal field. Some of the factors causing a barrier to its use in
practice will be addressed in more detail: i.e. test time by means of test choice and
abnormality criteria.
3.1.1 Test (Algorithm) choice
The lengthy test time for SWAP is an important factor and, as stated above, is one of the
reasons why SWAP is not routinely used in clinical practice. One way in which test time for
SWAP could be reduced is to consider the choice of algorithm. There are a number of test
programmes (algorithms) that can be used around which there is debate as to which should
be used. Current versions available for SWAP include a full-threshold option whereby a
staircase method is used to plot sensitivity at specific test locations [29]. A SITA-FAST
(Swedish Interactive Threshold Algorithm) version of the SWAP algorithm was developed
which reduced testing time by up to 70% (11 minutes with full threshold and just over three
minutes with SITA-SWAP) with no apparent reduction in sensitivity of specificity [30]. It is
also reported that the SITA-SWAP algorithm partially reduces the issue of the large inter-
subject variability by approximately 14% [29-31].
3.1.2 Abnormality criteria
The statistical properties of SWAP have been examined extensively, firstly by Wild et al [26]
who tried to establish a normal database containing probability levels and analysis
synonymous to that for SAP. An increased between level variability was found between
subjects compared to SAP with the variability increasing with target eccentricity and
increasing age. This is relevant as the risk of developing glaucoma increases with age[32].
The between subject variation is also important to note when looking at probability maps to
define an abnormal field. To use the same level of depression required for SAP would be
unwise as this will lead to a large number of false positive results. This adds evidence for the
need to design bespoke statistical analyses rather than a cross-over with SAP.
This view was also supported by Kwon et al. [33] showing a similar amount of variation upon
repeated testing. Both studies had a similar number of participants making their results
comparable, however, neither provided an indication of what may be an appropriate criterion
for what ‘normal’ may be.
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Polo and associates [25,34,35] aimed to suggest and refine abnormality criteria for SWAP by
addressing the sensitivity and specificity at different probability levels. They suggested that
using cluster point criteria (four points clustered at the P<5% level or three points clustered
lower than P<1%), rather than using global indices, provide the best sensitivity and
specificity. A criticism of the classification of the criteria they used to define glaucomatous
damage was inclusion of changes in the retinal nerve fibre layer as opposed to the gold
standard optic nerve head assessment (optic nerve images taken by photography). NICE
guidelines suggest optic nerve changes are more indicative of glaucomatous damage than
retinal nerve fibre layer assessment as the latter damage is not always present yet the
patient can have other characteristics of glaucoma including raised IOP, optic disc cupping
and visual field loss [36].
This view is also supported by Johnson et al [37] who suggested four abnormal points at the
P<5% level are indicative of glaucomatous visual field loss. Johnson and associates [37]
used their own controls in their study to define a normative database rather than the
parameters provided in the perimeter. However, they did test the validity of their controls
before comparing these with their ‘abnormal’ group and their normative dataset is large and
almost double that of Polo and colleagues [25,34,35] Although the normative database is
large the visual fields were only performed once on the control subjects who had no prior
knowledge of the test whereas the abnormal group had at least four years’ experience on
both SAP and SWAP. It has been shown that there is a significant learning effect for both
SWAP and SAP so it is possible the control subjects performed worse on the perimetry tests
which made them more comparable to the abnormal patients showing signs of reduced
sensitivity [38-40].
The work by Polo [25,34,35] and Johnson [37] is valuable and upon repeated testing Reus et
al. [41] found that Polo’s [25] criteria for abnormality on SWAP seemed to obtain more
positive results compared with Johnson’s criteria [37]. There was still a large variation in the
amount of positives obtained depending on which criteria were used. Reus et al. [41] allowed
for the learning effect which appears to improve specificity [42]. No indication was provided
regarding the end point of the study and subjects were not followed up to determine if SAP
defects persisted or developed.
There is little research to date that has specifically addressed the definition of an abnormality
criteria set for SWAP. Many studies use their own normative data and their own diagnostic
criteria as to what constitutes a defect. This introduces uncertainty as to whether SWAP can
be a clinically useful tool.  Further work is required to create a ‘’gold standard’’ diagnostic
criterion for SWAP in order to make direct comparisons between studies. A summary of the
studies attempting to define a abnormality criteria set is shown in Table 1.
3.1.3 SWAP and SAP
The initial SWAP studies followed ocular hypertensive and early glaucoma patients for five
years to determine whether SWAP was able to predict those patients who would go on to
develop glaucomatous visual field damage. Johnson et al. [13,14] and Sample et al. [43]
showed promise in the use of blue-on-yellow perimetry to detect visual field loss before
standard white on white perimetry but with a number of limitations. Explicit criteria for a
deficit on white on white perimetry was used (<5% probability level for mean deviation (MD)
or pattern standard deviation (PSD) or more than three points clustered at the <5% level).
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Table 1. Summary of studies attempting to define abnormality criteria for SWAP
Study Sample
Size
Control
Group
Used
Suggested Abnormality
Criteria
Follow up
Period
Kwon et al. [33] 31 eyes 33 eyes None suggested 8 weeks
Polo  et al. [25] 95 eyes 128 eyes Four clustered points at P<5%
level or three clustered points
at P<1% level
3 years
Johnson et al. [37] 479 eyes 348 eyes Four clustered points at
P<5% level
4 years
Reus et al. [41] 744 eyes None used Four clustered points at
P<5% level
6 months up
to 1 year
Van der Shoot
et al. [45]
416 eyes None used None suggested and compared
directly with SAP criteria of at
least 3 points at P<5% with
at least two at P<1% level or
corrected PSD <5%
7 to 10 years
Liu et al. [46] 132 eyes 37 eyes None defined Not reported
No such criterion was implemented for blue-on-yellow as to what actually constituted a
defect. It was evident there was a lot of variance even between tests with defects presenting
and disappearing upon repeated testing. Their initial test conditions did factor in absorption
of yellow light which is important as the ocular media can act as a neutral density filter
particularly in the presence of cataract [44]. Their sample size for which they base their
results on is relatively small for the amount of people potentially available with ocular
hypertension. One issue with the results obtained in the early studies was the reporting of
defects in terms of total deviations rather than pattern deviation which is important. Total
deviation provides an indication of the depression of the hill of vision whereas pattern
deviation gives an indication of the abnormality of the shape of the field. They did however
age match their patients but this was only against a maximum of 22 subjects. Considering
the variability that SWAP produces this may not be an entirely appropriate approximation of
glaucomatous field loss. The results from the papers published by Johnson and colleagues
[14,15] and Sample and colleagues [43] are what have driven subsequent studies.
Interestingly the subjects recruited by Polo and colleagues [34] to establish their abnormality
criteria were recalled three years later [35] to determine how many had developed a defect
on SAP. There was a high percentage who were deemed to have a SWAP defect and did
not go onto develop glaucomatous damage after three years indicating the specificity of the
test was not high and in the region of 30%.
There have been contradictions to the supporting evidence for SWAP. Van der Shoot et al
[45] state SWAP is less sensitive than SAP to predict conversion to glaucoma. However, in
their study, no correction criteria were provided for cataract which is known to decrease the
mean sensitivity of SWAP by absorption of the short wavelength light in the lens. This is
important considering that the age range used in their study would include those starting to
develop cataract [26]. The conversion to glaucoma, which was the end point of the study,
was based purely on visual field analysis. No anatomical correlation (e.g. optic nerve head
cupping) was sought that matched with the visual field defect.
Liu et al. [46] also supports that SWAP is not as sensitive as SAP for detecting glaucoma.
They used a sub analysis of early glaucoma as defined by the CIRRUS OCT which had
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been modified to ‘capture’ early glaucoma at the expense of specificity. With this method
they may however have included patients that otherwise would not have been considered
with solely visual field assessment.
3.2 Frequency Doubling Technology (FDT)
The frequency doubling phenomenon was first described by Kelly over 40 years ago[17].
When a low spatial frequency sinusoidal grating (<1 cycle/o) undergoes high temporal
counter phase flickering at 15Hz or greater, gratings appear to double to twice their actual
spatial frequency[47]. Essentially there is a rapid contrast reversal which light bars become
dark and vice versa.
The frequency doubling phenomenon is thought to be mediated by a subset (five per cent) of
ganglion cells within the magnocellular pathway called My cells [18,48]. Similar to the blue-yellow pathway cells the My cells have larger diameter axons making them more prone todamage in early glaucoma [21,49]. In order for FDT to be effective the spatial frequency
should be between 0.1 and 4 c/deg-1 (cycles per degree) and the temporal frequency greater
than 15Hz. Both are dependent upon retinal eccentricity in addition to a mean background
luminance of 50cd/m2[18,24].This forms the rationale for the use of FDT to detect
glaucomatous field damage earlier than SAP.
3.2.1 Test (Algorithm) choice
FDT first came into use in 1997[50].The first generation FDT manufactured by Welch Allyn
(Skaneateles Falls, New York, USA) used a 10o square stimuli, which was found to be
initially problematic as its large size prevented it from detecting small visual field defects
[24,51,52]. Second generation FDT was released in 2005 using a 5o square stimuli to
overcome this problem using the Humphrey Matrix visual field instrument [53,54]. The Matrix
test pattern was designed to be similar to the Humphrey Field analyser and Octopus
perimetry using a 0.43o round target on a 6o square matrix [50].
Screening programmes on the first generation FDT included the central 30 degrees of the
visual field. These algorithms used a modified binary search (MOBS) strategy. The algorithm
presents a grating at a level where 99% of normal subjects of an aged matched control
would see. If this is seen the zone is labelled normal, if this is not seen on a repeated
presentation then a grating at the 99.5% level is presented and increased until the stimulus
is seen [24,55]. The screening tests are performed in a supra-threshold pattern. Supra-
threshold is performed whereby the intensity of the stimulus shown is calculated to be above
the patient’s threshold. Threshold is performed where the stimulus is decreased in intensity
using an adaptive staircase procedure until no response is given [56].
Subsequent test programmes have been developed to reduce the test time for FDT. They
include rapid efficient binary search (REBS) and zippy estimation of sequential testing
(ZEST)[55]. REBS is based on the MOBS strategy but requires two response reversals
whereas MOBS requires four [55]. ZEST uses a probability density function at each location
(the probability that each subject will have that threshold) with patient responses modifying
the probability density function until the standard deviation of the probability density function
becomes sufficiently narrowed [57]. The results of FDT tests have been compared to a
normative database of 700 eyes and can be age matched [58].
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Isawe and colleagues [59] proposed that FDT could be an effective method of visual field
screening due to the short test time, its portability and relatively low-cost. Studies have
reported sensitivity for FDT ranging between 83% to 93% and specificities ranging between
55% to 100%[60-65]. FDT also appears to have lower test-retest variability and less of a
learning effect which makes it a promising emerging psychophysical test [66].
3.2.2 Abnormality criteria
FDT is similar to SWAP in that definitive criterion for what is defined as normal and abnormal
has not been uniformly decided upon. As Matrix FDT was released in 2005 there remains a
lack of large population longitudinal studies to assess what criteria would be most
discriminatory for a glaucoma diagnosis. Different criteria have been suggested although the
view for abnormal criteria appears to be reaching a more uniform decision compared with
SWAP.
Fogagnolo et al. [67] propose that the presence of at least one point at the P<5% level on
the pattern deviation plot (PDP) on the N-30 or C-20 screening programme is the most
suitable criteria for detecting glaucoma. Six different classifications of a defect were used
and analysed by receiver operator characteristic curves (ROC). A ROC curve plots true-
positive rate against the false positive rate [68]. The area under a ROC curve of 1 gives
100% sensitivity and specificity whereas a ROC of 0.5 would indicate no diagnostic value
[47]. The more stringent of the criteria did not significantly have a higher sensitivity or
specificity for detecting glaucoma which explains the author’s choice of defect criteria in
order to capture most glaucomatous loss. Patients included in the study had POAG to
enable the authors to identify the most sensitive and specific criteria for diagnosing
glaucoma. Definitions for glaucoma defects on SAP were in accordance with the guidelines
recommended by Hodapp-Parish-Anderson [70] which are also currently used by the
National Collaborating Centre for Acute Care [36] in the United Kingdom. The results for
sensitivity and specificity for visual field loss was comparable to those of others [63, 71-73]
and particularly in moderate and advanced glaucoma cases. Notably the authors found that
the screening programmes C-20 and N-30 showed a lower sensitivity for detecting nasal
step defects; one of the most common glaucomatous defects [70].
Brusini et al. [74] suggest PSD <5% and/or at least two areas on the PDP P<5% should be
used as the cut off criteria for the N-30 programme using the first generation FDT. Their
results with these diagnostic criteria were similar to those previously reported by Weinreb,
Medeiros & Sample [75] for the same programme.
A small cross sectional comparative study by Hong et al. [76] also suggest using more than
five points in the PDP at the P<5% level to discriminate between glaucomatous and non-
glaucomatous fields. This classification is more stringent than those proposed by Fogagnolo
et al. and Brusini et al. [67,74]. Hong and associates allowed for the influence of cataract on
visual field testing [77] which had not been accounted for in previous studies. All subjects
included in the study had manifest POAG detectable on SAP which were termed as early
defects i.e. MD not worse than -6dB. Both the normal and POAG group had a mean age of
under 40 which is significant as it is more likely that older individuals than in this age group
would be routinely screened for glaucoma [78]. ROC curves were used to analyse the
criteria proposed by the authors (MD P<1% and PSD P<5%) and appropriate statistical
testing was used. There was however a significant difference in the depth of defect between
the control group and the study group suggesting the criteria may be useful but only in the
age range of the population studied. Further work is required using these criteria for
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predicting visual field loss in at risk groups and for the learning effect to be taken account for
when considering a cut-off point.
Choi, Lee and Park [66] examined the use of the Humphrey Matrix perimeter for the
detection of pre-perimetric glaucoma and to define a clinically useful cut-off point. A strength
of the study is that the learning effect was allowed for both SAP and FDT by giving each
patient two practice attempts. Their initial ophthalmic investigation also included all gold
standard tests as defined by the National Collaborating Centre for Acute Care [36]. ROC
curves were used to determine which parameter (MD or PSD) provided the best
discriminating power. PSD was found to be the best discriminator which is in agreement with
Hong et al. [76].
Abnormality criteria are essential for defining a glaucomatous visual field when screening. As
is the current situation with SWAP, definitive criteria have not been agreed upon. However
evidence currently published does not show as much variation as what ‘abnormal’ should be
defined as on FDT when compared to defining SWAP abnormality criteria. There is a need
for more longitudinal studies taking into account for the variances that occur in the screening
population, the age of patients performing the test and where the criteria produce repeatable
defects. A summary of the studies attempting to define abnormality criteria is shown in Table
2 for direct comparison.
Table 2. Summary of studies attempting to define abnormality criteria for FDT
Study First Generation
or Matrix FDT
Sample
Size
Control
Group
Used
Suggested
Abnormality
Criteria
Follow up
Period
Fogagnolo et al. [67] First generation 40 eyes 40 eyes At least one
point at P<5%
on the PDP
Not
reported
Brusini et al. [55] First generation 258 eyes 60 eyes PSD <5%
and/or at least
two areas on
PDP at P<5%
Not
reported
Hong et al. [76] Matrix 36 eyes 24 eyes More than 5
points on PDP
at P<5%
Not
reported
Choi, Lee and
Park [66]
Matrix 99 eyes 122
eyes
PSD of  greater
than -3.14dB
Not
reported
3.2.3 FDT and SAP
Few studies exist that longitudinally compare FDT with SAP in respect to whether a subject
who presents with a defect on FDT would proceed to develop a defect on SAP. Many of the
early studies looking at agreement between FDT and SAP were conducted with subjects
who already had detectable manifest glaucoma [79,80].
A small prospective study by Quaranta et al. [81] examined the concordance of first
generation FDT with SAP in 25 manifest glaucoma patients and 25 ocular hypertensives
using MD plots; a measure of overall sensitivity loss. Although the study indicated a
significant correlation between MD in the glaucoma and ocular hypertensive group, they also
compare PSD but with no results presented other than ‘it was significant between groups’.
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There was no classification given as to what defines a visual field as glaucomatous or not
which makes it difficult to draw conclusions from. No follow up was performed in this study to
ascertain whether the defects persisted on repeated testing or whether the subjects showing
FDT defects in the ocular hypertensive group went on to produce defects on SAP.
In a larger study by Racette et al. [82] on 80 eyes, they found that first generation FDT was
better able to detect early glaucomatous damage than SAP using ROC analysis. Mean
deviation for SAP and PSD <5% for first generation FDT were found to be the best indicators
of early glaucomatous damage. However, there are issues with their definition of their
normal pressure. Routinely a pressure under 21mmHg is considered normal yet a cut-off
upper pressure of 23mmHg was used. The study has an advantage over the smaller study
by Quaranta and colleagues as they provide parameters to classify glaucomatous loss and
check for persistence of defects. Furthermore, they acknowledge the limitations of their
study and for longitudinal change, further studies are required.
Medeiros and associates [83] reported that first generation FDT defects were predictive of
future SAP defects in a longitudinal observational study over 17 months. The subjects were
retrospectively taken from a larger study (Diagnostic Innovations in Glaucoma Study) but
were not taken at random from the study group: the purpose being to include only subjects
at risk of developing POAG and not from secondary causes e.g. pigment dispersion
syndrome. This potentially introduces selection bias. It is interesting to note that the age
range of the sample taken is not given yet the authors found a statistically significant
difference between the age of subjects who converted and those who did not. The lack of
age range renders it difficult to consider the results for the population at risk. However, gold
standard tests were used to exclude manifest glaucoma as per National Collaborating
Centre for Acute Care guidelines [36] and allowances were made for learning effect [84].
More importantly the fields were repeated at follow up to determine if the defects persisted.
To reduce the influence of intra test variability and for a defect to be confirmed on SAP the
field was repeated three times. A normal database was used from a previous study
conducted by the authors in normal individuals and found 94% specificity upon using their
definition of an abnormal FDT (two points on MD P<5% level or a PSD of P<0.05%).
Fourteen out of the 105 eyes studied progressed to repeatable defects on both SAP and
FDT with the locations of the defects correlating. The results of this study show promise in
terms of a possible prediction of the development of SAP defects by location of repeatable
defects on FDT.
Spry, Hussin and Sparrow [80] compared the use of matrix FDT 24-2 threshold strategy with
the 24-2 SITA-Fast programme available on the HVF. The study was larger than that of
Quaranta et al. [81] and all patients went through gold standard assessment for detection of
glaucoma (SAP, gonioscopy, tonometry and optic nerve head examination) [36]. A strength
of the study was the classification of subjects into subgroups based on clinical examination
separating out the different types of glaucoma and suspects. In contrast to the Quaranta
study [81] the mean age of the study group was more representative of the patients
undergoing glaucoma testing. Upon comparison of MD and PSD moderate agreement was
found between the two techniques by means of a ROC analysis. The criteria used to define
a glaucomatous field were liberal and based upon clinical decision in order for it to be
applied to the clinical environment and the authors acknowledge that this may have led to
the high sensitivity found. Spry and associates [80] suggest that for the purposes of
glaucoma screening sensitivity should be compromised in order to optimise the specificity
and positive predictive value of FDT. In order to confirm the results further follow up is
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required to consider whether individuals who are screened with matrix FDT with the 24-2 test
pattern do develop defects that are synonymous with SAP.
3.3 FDT and SWAP
Both SWAP and FDT have been recognised as potential methods for the detection of early
glaucoma. Studies have looked at the comparability of FDT with SWAP with respect to
sensitivity and specificity and concordance with each other [27,46,85-89].
Landers and associates [85] reported that FDT and SWAP are comparable in terms of
sensitivity, specificity and concordance. Spry et al. [80] examined the diagnostic capability of
both SWAP and FDT. They reported that FDT had a lower test-retest variability (39% SWAP
compared to 34% FDT) but both methods had similar abilities in detecting early glaucoma.
One issue with the comparison is that FDT was not performed using the Welch Allyn nor
matrix FDT perimeter but on a ‘custom device’. Thus it is difficult to compare their results
with other studies using standard rather than customised assessments. Specifically, the 24-2
test pattern used for their FDT was a 4o diameter square which is not used in either the
Welch Allyn or matrix perimeter [50,51].  Gold standard tests were used however to classify
glaucoma and pattern deviation was used to classify defects rather than total deviation; the
latter providing a generalised impression of field loss. The use of PD or PSD is also
supported by Leeprechanon et al. [27] who found that, for matrix FDT, this provided the best
sensitivity and specificity. As for SWAP there is not a definitive definition of ‘abnormal’ as
previously discussed.
A prospective study by Horn et al. [87] attempted to overcome the limitations of previous
studies in order to determine whether SWAP and first generation FDT are able to detect pre
perimetric glaucoma, with interesting results. A double-bagging technique was used in the
study. The previous studies by Landers et al, Soliman et al. and Spry et al. [47,80,85] relied
upon making a clinical judgement regarding the outcome of the visual field testing. By using
the double bagging technique this standardises the outcome for all participants with all fields
being treated in the same way.  Horn et al. [87] recognised that the numbers assessed in
their study might not be sufficient to produce the most accurate, reliable or efficient algorithm
and therefore requires a larger study. The method itself may facilitate future study and allow
this area of research to finally move forward.
Matrix FDT was compared with SWAP in a prospective case-control study by Leeprechanon
et al. [7. The results showed a significant correlation between FDT and SWAP using MD and
PSD with FDT showing a higher sensitivity of detecting glaucoma (72% versus 54%). The
sample size was small, however the 24-2 test pattern used for both FDT and SWAP allowed
for a more direct comparison of results. A strength of the study was that concordance of the
location of the defect was investigated with a 72% agreement reported. When considering
the indices PSD and PD at the P<5% level they were significantly higher in the early
glaucoma group versus the normal group on FDT but not on SWAP suggesting that FDT
may be better at filtering out the generalised  noise which is known to occur in SWAP.
More recently Liu et al. [46] found matrix FDT to be more sensitive than SWAP in detecting
glaucoma at comparable levels of specificity. The criteria used for defining an abnormal
visual field for FDT and SWAP was the same as that for SAP for which there is contention as
to whether SAP criteria can be used for other visual field assessment methods [26,66].
Furthermore, the confidence intervals overlapped for matrix FDT and SWAP results which
may indicate that there is little difference in the diagnostic abilities of SWAP and matrix FDT.
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A subgroup analysis was performed with patients with ‘early glaucoma’ but no definition of
early glaucoma was provided.  The results reported by Liu et al. [46] were in agreement with
those of Leeprechanon et al. [27] in their larger sample size.
4. CONCLUSION
With an aging population and the rise in the prevalence of glaucoma worldwide there is a
clear need for rapid diagnosis to commence treatment early to preserve both vision and
visual field. The need for rapid diagnosis however does need to be considered from an
economic perspective i.e. is the time and money spent on diagnosing glaucoma earlier
clinically useful providing the best cost: benefit ratio.
There is evidence available to show that SWAP, first generation and matrix FDT have
potential as psychophysical tests for earlier glaucoma detection. SWAP has been
investigated at a greater length than the more recently emerging FDT methods. Both SWAP
and FDT lack defined abnormality criteria like those that exist for SAP. Until this is
established it is difficult to determine whether or not the tests have a role in either glaucoma
screening in the community or at the first visit to the hospital eye service. SWAP has the
issue of a large inter and intra subject variability requiring up to five attempts before the
patient becomes sufficiently reliable. This has time and economic implications which need to
be considered. FDT shows less variability with more repeatable results and lesser learning
effect. The testing time is also short with FDT which again may make it a more favourable
test than SWAP.
SWAP and FDT on direct comparison have been found to have similar sensitivity and
specificity in predicting glaucomatous visual field loss and show moderate agreement with
SAP for detecting field loss. Few studies however consider whether the defects correlate
between tests and, in SWAP and FDT, whether the defects develop in the same location as
that in SAP. This is a question requiring further research given that SWAP (which uses blue
stimuli to isolate the S cones and K pathway) may be more relevant to central perimetry
within 10 degrees of fixation whereas FDT (which uses fast reversal, large contrast stimuli to
isolate the M pathway) may be more relevant to perimetry peripheral to the central 10
degrees. There is a lack of longitudinal studies addressing persistence of defects and
anatomical correlation of defects to be able to definitively ascertain the clinical application of
both FDT and SWAP. Further research is thus recommended to answer these outstanding
questions.
To conclude both SWAP and FDT could potentially be used as methods for earlier glaucoma
detection but require well-defined, consistent abnormality criteria within specified testing
algorithms. Currently, standard automated perimetry remains the preferred choice for clinical
assessment until such time that evidence shows SWAP and/or FDT techniques to be
superior in respect to accuracy and reliability in the detection of early visual field loss in
glaucoma.
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